GE HealthCare Technologies heads into its Q2 earnings release with an unusual tension: short sellers have been piling in at the fastest pace in months, yet the stock just posted its best daily gain of the week and the broader analyst consensus still sees meaningful upside from here.
The short interest story is the sharpest signal this week. Bears have added aggressively — SI as a percentage of the free float climbed roughly 33% over the past month, reaching 4.3% of float on 19.7 million shares short as of July 28. The week-on-week build was nearly 20%, a notably concentrated move. That acceleration began around July 22, when SI jumped from 16.2 million to 17.4 million shares in a single session, then pushed further to 21.4 million by July 24 before a partial unwind. Despite the build, the borrow market remains far from stressed. Availability is extraordinarily loose — shares available to borrow stand at roughly 14 times the current short position, a reading that signals no friction for bears wanting to establish or exit positions. Cost to borrow is running at just 0.43%, well below levels that would indicate a crowded trade. The short score of 39.6 is middling, off its July 24 high of 42. In short, the recent SI build looks deliberate rather than desperate — bears have been adding into the earnings print, but the borrow market is not signalling any squeeze risk.
Options tell a calmer story. The put/call ratio has actually eased to 0.57, slightly below its 20-day average and near the 52-week low of 0.51. That means options positioning is, if anything, leaning constructive — call demand is strong relative to puts, the opposite of what you'd expect if the market were broadly bracing for a miss. The z-score of -0.80 confirms options positioning is softer on the defensive side than usual. Together with the loose borrow market, this argues that the short build is coming from a directional bearish bet, not broad hedging activity.
The Street is cautiously constructive, though not uniformly bullish. BTIG's Ryan Zimmerman raised his price target to $79 this morning, maintaining a Buy — a timely vote of confidence ahead of the numbers. That sits comfortably above the mean analyst target of around $81, which implies roughly 26% upside from the $64.11 close on July 28. UBS trimmed its target to $67 from $69 last week while keeping a Neutral rating, and two new initiations — BMO Capital at Market Perform ($70) and RBC at Outperform ($80) — show the Street is still actively debating the stock's trajectory. The Goldman Sachs downgrade to Neutral at end of April, when the stock was being marked to $65 targets across several major desks, appears to have marked a sentiment trough; the direction of travel since then has been incrementally more positive. On valuation, the PE sits at 12.4x, EV/EBITDA at 8.7x — neither reading is demanding for a company with roughly half its revenue recurring. The EV/EBIT factor score ranks in the 80th percentile versus peers, suggesting GEHC looks reasonably valued on an operational earnings basis. EPS momentum is softer — the 90-day rank at the 29th percentile and the earnings surprise rank at 44 — pointing to a consensus that has already been reset lower over the past quarter.
One institutional data point worth noting: Dodge & Cox added 3.1 million shares in its most recently reported quarter, lifting its position to 31.3 million shares (6.9% of the company). Barrow, Hanley also added 5.4 million shares. Both are value-oriented managers, and their accumulation at prices broadly in the current range suggests the valuation case is resonating with longer-horizon investors even as shorter-term traders remain cautious.
The insider picture adds texture. In late April and early May, eight insiders — including the CEO, CFO, General Counsel, and independent director H. Lawrence Culp (who put in $5 million) — all bought shares in a tight cluster around the $60-$64 level. Net insider buying over the 90-day window totalled over $6.7 million. That cluster of executive buying at prices very close to today's level suggests management did not view that range as a significant overvaluation.
Peers had a strong week. SYK gained over 10%, BAX nearly 10%, and STE close to 9% — all outpacing GEHC's 3.3% weekly move. Whether GEHC closes that gap depends almost entirely on the reception to earnings results, with the stock's reaction to today's Q2 print — announced July 29 — the immediate focus for anyone watching the positioning divergence between a rising short book and a constructive options market.
See the live data behind this article on ORTEX.
Open GEHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
